Esperion Update On Lead Cholestrol Drug Spooks Investors
This article was originally published in Scrip
Worries Esperion Therapeutics is falling behind competitors in the race to bring the next generation of powerful cholesterol-lowering drug to market suddenly surfaced this week, sending the US biotech's share price plummeting more than 40% on Tuesday.
You may also be interested in...
Esperion Therapeutics and the FDA have failed to reach agreement on a definitive approval path for the company's cholesterol drug ETC-1002, raising the possibility of a long and more expensive development pathway for the oral therapy.
Evotec’s multimodality approach to drug discovery landed the biotech two new discovery collaborations this week, underscoring its emphasis on patient-driven data.
Novo Nordisk and Evotec will identify and develop novel drugs for treating chronic kidney disease, using datasets of CKD patients provided by the Danish group and from other sources.